Valproate Level: Nursing Guide
Valproate level measures total serum valproic acid to support therapeutic drug monitoring in epilepsy and bipolar disorder — but FDA labeling notes the concentration–response relationship is not well documented for every patient. Pair results with confusion, tremor, nausea, jaundice, seizure control, and concurrent liver function tests.
Contents
Quick Facts
Key Takeaway
The main nursing priority is pairing the level with neurologic status, liver injury cues, platelet trends, and exact dose timing before any dose change.
Specimen & Collection Details
Nurse quick-reference for collection prep that affects result quality.
Red top or gold (serum separator) per laboratory protocol
Serum specimen for total valproic acid — follow the reporting laboratory tube and centrifugation requirements
Serum (venous) for total valproic acid concentration
Turnaround and screening rules vary by institution; follow local policy — follow local laboratory minimum serum volume
Trough specimen before the next scheduled dose when monitoring steady state per prescriber and laboratory protocol; document exact draw time relative to last dose
No special preparation is usually required — follow prescriber and local laboratory instructions; do not withhold scheduled valproate unless prescriber orders a hold
Transport serum to chemistry/therapeutic drug monitoring laboratory promptly per institutional policy
Turnaround and screening rules vary by institution; follow local policy — routine TDM often same-day; stat timing varies by institution
Chemistry / therapeutic drug monitoring laboratory
What is Valproate Level?
Valproate Level measures total valproic acid concentration in serum. Valproate (valproic acid and divalproex formulations) is used as an anticonvulsant and mood stabilizer. FDA labeling states the relationship between plasma concentration and clinical response is not well documented for all patients because nonlinear, concentration-dependent protein binding affects clearance — so nurses interpret levels with symptoms, dose timing, and trends rather than a single number alone.
Overview
Nurses order, collect, and act on valproate levels on neurology wards, psychiatric units, and outpatient clinics when patients take valproic acid or divalproex for seizures or mood stabilization. FDA labeling notes plasma levels are often measured when clinical response is unsatisfactory, toxicity is suspected, or interacting medicines change exposure — especially enzyme-inducing antiepileptic drugs such as carbamazepine or phenytoin.
On this Tests & Diagnostics page, nursing focus is interpretation, trough timing, and escalation — not step-by-step venipuncture technique (see the Performance procedure guide). Pair valproate level with complete blood count and platelet count for thrombocytopenia monitoring, ammonia when encephalopathy is suspected, and neurological assessment for sedation, ataxia, and seizure control.
Before collection: confirm last valproate dose time, whether the order specifies trough or random timing, and current seizure or mood symptoms. After the result: compare to the reporting laboratory interval, review liver function and platelet trends, and escalate when FDA-described hepatotoxicity or CNS depression signs appear — never change valproate dose without prescriber authorization.
Valproate Toxicity, Hepatotoxicity, and TDM Safety
Supratherapeutic valproate with somnolence, ataxia, or rising liver enzymes requires prescriber notification — nurses do not independently change dose. Document trough timing and concurrent medicines before acting on a single level.
- Trough 132 mcg/mL with new ataxia and somnolence on divalproex
- FDA-described hepatotoxicity prodrome — malaise, vomiting, facial edema, loss of seizure control
- Critical institutional valproate value (for example ≥151 mcg/mL at some reference laboratories)
- Post-dose peak draw mislabeled as trough leading to false supratherapeutic interpretation
Document: last dose time, draw time, symptoms, LFT and platelet trends, and escalation communication.
What Valproate Level Can and Cannot Tell You
This test can help identify:
- Total serum valproic acid exposure for TDM and toxicity assessment
- Subtherapeutic or supratherapeutic trends when paired with verified trough timing
- Need for prescriber review after medicine interactions or adherence concerns
- When free valproate testing may be warranted in hypoalbuminemia per prescriber
This test cannot:
- Reliably reflect bioactive drug in every patient because of protein binding per FDA labeling
- Replace neurologic assessment, seizure observation, or liver monitoring
- Diagnose non-adherence without MAR review and dose timing context
- Provide one universal critical value for all institutions
Serial Valproate Levels and Delta Interpretation
FDA labeling notes routine monitoring is not required for every patient, but serial troughs matter when toxicity, interactions, or poor control emerge. Compare today's level to prior troughs drawn at the same interval before the next dose.
| Trend pattern | Clinical meaning | Nursing action |
|---|---|---|
| Rising trough with new sedation or ataxia | Possible toxicity or interaction | Notify prescriber; fall and seizure precautions; repeat LFTs/CBC per order |
| Stable trough with breakthrough seizures | May not reflect adherence or free fraction | Review MAR; assess symptoms; notify prescriber — evaluate outcomes after plan change |
| Falling trough after enzyme inducer started | Increased clearance per FDA interactions | Document medicine change; notify prescriber; increase monitoring frequency per order |
| High trough with rising ALT | Hepatotoxicity concern especially in first six months | Urgent prescriber notification; implement protocol monitoring; hold drug only per order |
Pre-draw Checks for Trough Valproate Level
Verify
Clarify before proceeding when:
- Order says trough but draw would occur soon after a dose
- Missed or double doses in MAR make timing interpretation unreliable
- Patient has acute hepatic symptoms without recent LFTs
- New carbapenem or enzyme-inducing AED started but level frequency not updated
- Critical result has not been acknowledged by the responsible clinician
- Level conflicts strongly with exam — for example therapeutic trough with severe toxicity signs
Reading Valproate Level With Symptoms, LFTs, and Trends
Interpret valproate level with dose timing, symptoms, liver enzymes, platelets, and prior troughs. FDA labeling cites 50–100 mcg/mL as a commonly accepted therapeutic range, but some patients are controlled outside that band.
| Level context | Clinical meaning | Nursing focus |
|---|---|---|
| Supratherapeutic trough with CNS signs | Valproate toxicity risk | Notify prescriber; neurologic monitoring; do not change dose independently |
| Therapeutic trough with breakthrough seizures | May still be inadequate control or adherence issue | Review MAR and symptoms; notify prescriber; evaluate outcomes after plan change |
| Subtherapeutic trough at correct timing | Under-exposure or interaction | Assess seizure or mood status; verify medicines; notify prescriber |
| High level with rising ALT | Hepatotoxicity pathway | Urgent escalation per FDA hepatotoxicity warning and facility protocol |
Reference ranges, critical values, and protocols may vary by laboratory, institution, patient population, and testing method. Always follow local policy and the reporting laboratory’s reference range.
Trough Timing, Protein Binding, and Collection Traps at the Bedside
| Bedside point | Nursing note |
|---|---|
| Trough timing | Draw before the next dose when ordered — document hours since last dose |
| MAR adherence | Missed or extra doses change interpretation more than a single number |
| Protein binding trap | Low albumin may elevate free drug despite normal total level |
| Interaction alert | Carbapenems and enzyme inducers can shift levels quickly — notify prescriber |
| Outcome tracking | Evaluate outcomes with serial levels, LFTs, symptoms, and seizure control — not one trough alone |
Valproate TDM in Epilepsy and Mood-Stabilizer Pathways
Diagnostic safety badge: Critical-result test — prompt review and escalation may be required when supratherapeutic levels accompany CNS or hepatic toxicity signs.
Check-before-test protocol
- Confirm trough indication and last dose time
- Review interacting medicines and adherence
- Collect timed serum with dose documentation
- Interpret with LFTs, platelets, and neurologic exam
- Escalate hepatotoxicity or CNS toxicity red flags per protocol
Critical teach-back questions
- “Can you tell me why we check valproate levels and why timing before your next dose matters?”
- “What symptoms — extra sleepiness, unsteady walking, yellow skin, or easy bruising — should you report right away?”
- “Can you tell me what to do if you miss a dose or start a new antibiotic?”
Care coordination: prescriber, neurology or psychiatry team, pharmacy, laboratory/TDM, and rapid response per facility protocol when acute toxicity is suspected.
Valproate Level Quick Clinical Checklist
- Was this a true trough draw with last dose time charted?
- Did I compare the level to symptoms, LFTs, platelets, and prior troughs?
- Are new enzyme inducers or carbapenems documented and reported?
- Am I treating the laboratory interval as guidance — not automatic dose instruction?
- Who must be notified now if hepatotoxicity or CNS toxicity signs are present?
Why Valproate Level is Ordered
Valproate level is ordered when clinicians need serum concentration data to support dose adjustment, toxicity evaluation, or adherence assessment in patients receiving valproic acid therapy.
| Clinical Indication | What the Test Answers | Nursing Rationale |
|---|---|---|
| Unsatisfactory seizure or mood control on valproate | Is the patient still having breakthrough seizures or mood episodes despite therapy? | FDA labeling states plasma levels may be measured when satisfactory clinical response has not been achieved to determine whether concentration is within the commonly cited 50 to 100 mcg/mL therapeutic range. |
| Suspected valproate toxicity | Are there CNS depression, ataxia, tremor, or rising liver enzymes with valproate use? | the reporting laboratory notes major side effects such as CNS depression, thrombocytopenia, and hepatic dysfunction are more likely when peak levels regularly exceed 125 mcg/mL — nurses correlate levels with exam and concurrent labs. |
| Medicine interaction or adherence concern | Did an enzyme inducer start or stop, or does history suggest missed doses? | FDA labeling notes enzyme-inducing antiepileptic drugs increase valproate clearance; carbapenem antibiotics may drop levels to subtherapeutic range — monitoring frequency should increase after such changes. |
| Renal impairment, hypoalbuminemia, or elderly patient on valproate | Could altered protein binding make total level misleading? | FDA labeling warns total serum valproate may not reflect bioactive drug when protein binding is reduced — free valproate testing may be considered per prescriber and laboratory protocol. |
Contraindications and Precautions
There is no absolute contraindication to valproate level testing when results may change management. Valproic acid itself is contraindicated in significant hepatic disease per FDA labeling — coordinate testing with prescriber when acute liver failure is suspected.
- Suspected valproate hepatotoxicity — malaise, weakness, lethargy, facial edema, anorexia, vomiting, or loss of seizure control per FDA boxed warning
- Supratherapeutic level with new ataxia, somnolence, tremor, or declining mental status
- Laboratory critical value per reporting institution (for example ≥151 mcg/mL at some reference laboratories) or rapid rise between serial levels with toxicity signs
- Post-dose rather than trough draw may show peak levels above target without true toxicity
- Total level may mislead when hypoalbuminemia, hepatic disease, or renal impairment increase free fraction per FDA pharmacology section
- Some patients are controlled below or above the commonly cited 50–100 mcg/mL range — do not treat the laboratory interval as a universal dose rule
- New jaundice, rising transaminases, or FDA-described hepatotoxicity prodrome on valproate.
- Critical or markedly supratherapeutic valproate level with CNS depression, ataxia, or thrombocytopenia per institutional policy.
- Breakthrough seizures despite reported therapeutic level — evaluate adherence, timing, interactions, and need for free valproate or alternative therapy.
Patient Preparation
No special fasting is usually required, but nurses verify dose timing for trough specimens, concurrent medicines, pregnancy status, and liver monitoring orders per FDA and institutional protocol.
Pre-test checksReview enzyme-inducing antiepileptic drugs (carbamazepine, phenytoin, phenobarbital), carbapenem antibiotics, aspirin, and other protein-binding displacers that alter valproate levels per FDA drug interaction sections. Never hold valproate or change dose without prescriber order while awaiting results.
Performance — nursing procedure guide
This page is a Tests & Diagnostics guide for Valproate Level. It emphasizes why the test is ordered, how to interpret results, when to escalate, and preparation factors that affect validity — not step-by-step performance technique (those live under Nursing Procedures when available).
Step-by-step technique, supplies, infection prevention, and immediate post-procedure monitoring for this test are covered in:
Use the Patient preparation, Results and interpretation, and Nursing responsibilities sections on this page for order verification, pre-analytic checks, result follow-up, critical-value escalation, and documentation.
Result follow-up at a glance
Nursing workflow on this page — from order to safe action on results:
Results and Interpretation
Total valproic acid is reported in mcg/mL (μg/mL). FDA labeling cites a commonly accepted therapeutic range of 50 to 100 mcg/mL, though some patients may be controlled outside that band. the reporting laboratory lists therapeutic guidance of 50 (trough) to 125 (peak) mcg/mL with institution-specific critical thresholds — always use the reporting laboratory reference interval and interpret with dose timing and clinical findings.
Reference ranges, critical values, and protocols may vary by laboratory, institution, patient population, and testing method. Always follow local policy and the reporting laboratory’s reference range.
| Result | Range / Finding | Clinical Meaning | Nursing Action |
|---|---|---|---|
| Within reference interval | Within prescriber target or reporting laboratory therapeutic interval (often roughly 50–100 mcg/mL total valproate per FDA labeling) | Serum concentration within the cited therapeutic band at the documented draw time — does not alone prove seizure control or absence of toxicity | Continue monitoring per protocol; trend levels with symptoms, LFTs, and platelets; document adherence teaching |
| Borderline / near reference limit | Near upper or lower laboratory limit without clear toxicity or breakthrough symptoms | May warrant prescriber review — FDA notes some patients tolerate higher or lower levels | Notify prescriber per protocol; repeat trough with verified timing before dose changes |
| High / above reference interval | Above therapeutic interval or institutional supratherapeutic threshold | Increased exposure — FDA and Mayo references associate high levels with CNS depression, thrombocytopenia, and hepatic dysfunction risk, especially when peaks regularly exceed 125 mcg/mL | Neurologic and bleeding assessment, prescriber notification, repeat level timing review, and escalation per toxicity protocol — do not independently reduce dose |
| Low / below reference interval | Below therapeutic interval at documented trough timing | Possible subtherapeutic exposure — consider adherence, interaction, or inadequate dosing | Assess breakthrough seizures or mood symptoms; notify prescriber; verify dose administration and interacting medicines |
Toxic and Supratherapeutic Valproate Level Escalation
Critical thresholds vary by laboratory — the reporting laboratory cites ≥151 mcg/mL as a critical value for total valproic acid, while UF Health lists toxicity concern above 100 mcg/mL in general reference material. Escalate when critical values or high levels accompany FDA-described hepatotoxicity, CNS depression, thrombocytopenia, or hyperammonemic encephalopathy signs per facility policy.
| Critical Finding | Threshold / Value | Immediate Action |
|---|---|---|
| Institutional critical valproate level | At or above laboratory critical limit (for example ≥151 mcg/mL at the reporting laboratory) | Immediate prescriber notification, neurologic assessment, hold valproate only per order, and escalation according to facility protocol |
| Supratherapeutic level with CNS toxicity signs | Elevated level with somnolence, ataxia, tremor, or confusion | Continuous neurologic monitoring, prescriber notification, and evaluate outcomes after intervention — consider ammonia and LFT trends |
| Rising level with hepatotoxicity prodrome | Increasing valproate level with malaise, vomiting, jaundice, or rising transaminases during first six months of therapy per FDA warning | Stop valproate only per prescriber order; urgent escalation; document symptoms and laboratory trend with closed-loop communication |
Stop routine workflow and escalate according to facility policy when the patient has FDA-described hepatotoxicity signs, critical or rapidly rising valproate level with CNS depression, severe thrombocytopenia, or hyperammonemic encephalopathy — even if a prior level appeared therapeutic.
Factors Affecting Results
Valproate levels reflect dose, timing, protein binding, drug interactions, and organ function. Nurses document factors that affect validity and interpretation.
- Peak draw shortly after dose — may appear supratherapeutic without true toxicity
- Assuming high total level equals high active drug when hypoalbuminemia increases free fraction
- Single elevated level without symptoms — may still warrant prescriber review but requires trend
- Therapeutic total level while free fraction is elevated in hepatic or renal impairment
- Subtherapeutic trough with missed doses not yet reflected in MAR review
- Normal level interpreted as adequate control while breakthrough seizures continue
- Enzyme-inducing antiepileptic drugs — increase valproate clearance per FDA labeling
- Carbapenem antibiotics — may reduce valproate to subtherapeutic levels per FDA labeling
- Hypoalbuminemia, hepatic disease, renal impairment, and aspirin — alter protein binding
Total serum valproate cannot provide a reliable index of bioactive drug in all patients because of concentration-dependent protein binding per FDA labeling. The test does not replace neurologic assessment, liver monitoring, platelet surveillance, or seizure observation. Routine monitoring is not required for every patient — clinical response and toxicity signs guide urgency. Reference ranges and critical values vary by laboratory.
Nursing Responsibilities
Nursing responsibilities center on trough timing verification, accurate dose documentation, trend interpretation with symptoms and concurrent labs, and urgent escalation when FDA-described hepatotoxicity or CNS toxicity appears.
Before the TestDocumentation
Documentation must link valproate level to dose timing, draw time, clinical status, concurrent labs, and escalation response.
“Trough valproate level drawn 06:42 (13 h after last 500 mg divalproex DR dose at 17:30). Result 132 mcg/mL (reference 50–100 mcg/mL lab interval) — patient somnolent with new ataxia; ALT 186 U/L trending up; platelets 98 ×10⁹/L; prescriber notified via SBAR; valproate held per order; repeat trough and ammonia pending.”
- Draw time, last dose time, formulation, and trough vs random designation
- Neurologic status, seizure activity, and sedation level at collection
- Valproate value with reporting laboratory reference and critical flags
- Concurrent LFT, CBC, and ammonia results or pending status
- Prescriber notification with read-back when critical or toxic level
- Adherence teaching and safety precautions after result communication
Patient and Family Education
Use plain language: the blood test shows how much valproate is in the body to help the team keep seizures or mood symptoms controlled while watching for side effects.
Valproate Level NCLEX practice questions
Practice NCLEX-style clinical judgment focused on Valproate Level safety and nursing judgment. Use the case tabs (orders, results, assessment, nursing notes), then answer eight Next Gen–style items (including an ordered workflow step) and evaluate outcomes with the answer key.
Select a tab to view orders, results, assessment, and nursing note details for this case.
- Order: Trough valproate level; CBC; LFTs; ammonia if ordered
- Indication: Epilepsy on divalproex — new somnolence and ataxia; trough level ordered
- Timing: Specimen drawn 07:10, scheduled trough before 07:30 morning dose
- Related orders: Repeat valproate level in 48 h; neurology consult if symptoms persist
- Result: Total valproate 132 mcg/mL (reference 50–100 mcg/mL on report)
- Trend / prior value: Prior trough 88 mcg/mL one month ago; ALT rose from 42 to 186 U/L over two weeks
- Pending tests: Repeat trough and ammonia pending; prescriber reviewing carbamazepine interaction
- Vital signs: HR 88/min, BP 118/72 mmHg, RR 14/min, SpO₂ 97% room air, temp 36.8°C
- Symptoms: Increased sleepiness, unsteady gait, fine hand tremor, no active seizure
- Focused assessment: Alert but drowsy; ataxic gait; no jaundice; bruises on forearms noted
- Preparation notes: MAR shows missed evening dose two days ago then double dose — adherence issue flagged
- Collection events: Serum tube labeled with trough timing; sent to TDM laboratory
- Teaching gaps / safety concerns: Supratherapeutic trough with rising LFTs, thrombocytopenia trend, and CNS sedation
Answer key & rationale
Frequently Asked Questions
FAQ
What does a valproate level test measure?
It measures total valproic acid concentration in serum, most often used for therapeutic drug monitoring in patients taking valproate for seizures or mood stabilization.
What is the usual therapeutic range for total valproate?
FDA labeling commonly cites 50 to 100 mcg/mL, though some reference laboratories use broader trough-to-peak guidance. Always follow the reporting laboratory interval and prescriber target.
When should a trough valproate level be drawn?
When the order specifies trough monitoring, draw immediately before the next scheduled dose and document exact dose time — peak draws can mislead interpretation.
Can a normal level rule out valproate toxicity?
No. FDA labeling notes total serum valproate may not reflect bioactive drug because of protein binding, and hepatotoxicity can occur with nonspecific symptoms even when levels seem therapeutic. Always assess liver enzymes, platelets, and neurologic status.
What medicines commonly change valproate levels?
FDA labeling highlights enzyme-inducing antiepileptic drugs and carbapenem antibiotics that may lower levels, plus medicines that alter protein binding. Report new antibiotics or seizure medicines to the prescriber.
Should nurses change valproate dose when the level is high?
No — notify the prescriber with clinical context and implement monitoring and safety measures per order. Dose changes require prescriber authorization.
What symptoms suggest urgent escalation on valproate?
FDA boxed warning lists malaise, weakness, lethargy, facial edema, anorexia, vomiting, loss of seizure control, jaundice, severe sedation, and bleeding. Escalate according to facility policy when these appear.
References
References
-
U.S. Food and Drug Administration. Valproic Acid Capsules — Prescribing Information. DailyMed.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=002d4c7e-b94e-49b6-8554-0aa0c60d5bde
-
Mayo Clinic Laboratories. Valproic Acid, Total, Serum (VALPA). Test Catalog.https://www.mayocliniclabs.com/test-catalog/overview/37066
-
Mayo Clinic Laboratories. Valproic Acid, Free and Total, Serum (VALPG). Therapeutics Catalog.https://therapeutics.testcatalog.org/show/VALPG
-
UF Health. Therapeutic Drug Levels. University of Florida Health.https://ufhealth.org/conditions-and-treatments/therapeutic-drug-levels
-
Mayo Clinic Laboratories. Valproate — Drug Book. Test Catalog.https://www.mayocliniclabs.com/test-catalog/drug-book/specific-drug-groups/valproate
-
Cotariu D, Zaidman JL. Valproic acid and the liver. Clin Chem. 1988.https://pubmed.ncbi.nlm.nih.gov/3365676/
-
National Institute for Health and Care Excellence. Epilepsies in children, young people and adults (NG217). NICE.https://www.nice.org.uk/guidance/ng217
-
National Library of Medicine. Valproic Acid. MedlinePlus.https://medlineplus.gov/druginfo/meds/a682412.html
Editorial Standards & Medical Review
About the author: Sid A. Abdala Balal, RN, writes evidence-based nursing education focused on diagnostic safety, clinical interpretation, and bedside nursing judgment.
Medical review: This guide is reviewed by Dr. Adam Sayedi, MD, for clinical accuracy, diagnostic safety, and alignment with current standards for Valproate Level.
Policies: Medical Review Process · Editorial Policy · Correction Policy